Announcement

Collapse
No announcement yet.

China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

Collapse
X
 
  • Filter
  • Time
  • Show
Clear All
new posts

  • China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

    China NMPA Approves Optune® for the Treatment of Newly Diagnosed and Recurrent Glioblastoma

  • #2
    Al Musella's Comments: (This is his personal views and are not necessarily the views of the Musella Foundation!)

    Optune is finally available in China - 6 years after we had it here in the USA!

    In China there are about 45,000 patients diagnosed per year with glioblastoma. That is more than double the number here in the USA.

    The press release states: A large, global phase 3 pivotal clinical study in newly diagnosed glioblastoma showed adding Optune to chemotherapy more than doubled the five-year overall survival rate1

    Comment

    Working...
    X